Cargando…
Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer
Treatment for ovarian cancer remains challenging despite a high initial response rate to first line platinum-taxane treatment. Most patients eventually experience recurrence and require further treatment. Persistent activation of STAT3 is associated with cancer growth and progression and is also inv...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966246/ https://www.ncbi.nlm.nih.gov/pubmed/29849942 http://dx.doi.org/10.18632/oncotarget.24368 |